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University School of Medicine, Shanghai, ChinaAbstractPrediction of antiviral efﬁcacy prior to treatment remains largely unavailable. We have previously demonstrated the clinical value of on-
treatment hepatitis B virus (HBV) reverse transcriptase (RT) quasispecies (QS) evolution patterns. In this study, we aimed to elucidate
the relevance for prediction of pretreatment HBV RT QS characteristics by comparing the performance of next-generation sequencing
(NGS) and clone-based Sanger sequencing (CBS). Thirty-six lamivudine-treated patients were retrospectively studied, including 18
responders and 18 non-responders. CBS and NGS data of pretreatment serum HBV were used to generate RT QS genetic complexity
and diversity scores, according to our previous studies. The ability of both methods to predict responsiveness was evaluated with
receiver operating characteristic (ROC) curves. A cut-off value was generated on the basis of prediction ability. Responders had
signiﬁcantly higher pretreatment RT QS genetic complexity and diversity (in the ﬁrst two parts, which overlapped with the S gene, at
both the nucleotide and amino acid levels) than non-responders by NGS-based testing. NGS-based algorithms predicted response better
than CBS in the ROC curve analysis. The mean distance of the second contig had the highest area under the curve (AUC) value. When
the cut-off value was set to 0.007186, the difference between survival curves was signiﬁcant (p 0.0090). Pretreatment HBV RT QS
heterogeneity in the overlapping region of the RT and S genes could be a predictor of antiviral efﬁcacy. NGS improves the predictions of
virological outcomes relative to CBS algorithms. This may have important implications for the clinical management of subjects chronically
infected with HBV.
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virus (HBV) quasispecies (QS) evolution patterns during early
nucleos(t)ide analogue antiviral therapy [1,2]. With clone-based
Sanger sequencing (CBS) approaches, our group found that theClin Microbiol Infect 2015; 21: 797.e1–797.e8
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.03.021
797.e2 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIdynamic changes in HBV QS within the reverse transcriptase
(RT) region showed distinct patterns between responders and
non-responders during the early stage of lamivudine treatment,
and that the dynamic changes in RT QS complexity and di-
versity during the ﬁrst 4 weeks were correlated with lam-
ivudine antiviral efﬁcacy and antiviral resistance-related
mutations. However, molecular cloning and sequencing is highly
time-consuming and laborious, and the representative value of
the clone method is limited by the number of clones obtained.
Therefore, in order to study in depth the differences and
clinical application of QS characteristics, we then set up a QS
study methodology [3] based on massively parallel ultra-deep
DNA pyrosequencing, one of the high-efﬁciency next-genera-
tion sequencing (NGS) [4] methods. NGS can maximize the QS
sampling capacity so that it approaches the real QS population.
The enhanced ability to detect minority drug resistance variants
by NGS has already been well documented in HBV infection [5].
In the current study, the focus was on the clinical relevance of
pretreatment HBV RT QS characterized with both the CBS
method and the NGS method.Patients and methodsPatients
Thirty-six chronic hepatitis B patients were retrospectively
enrolled in this study. All patients were treatment-naïve prior
to antiviral therapy. All of them were hepatitis B surface antigen
(HBsAg)-positive and had elevated HBV DNA (HBV DNA of
>2000 IU/mL) and serum alanine aminotransferase (ALT) levels
higher than twice the upper limit of normal before lamivudineClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttreatment. Exclusion criteria included hepatitis C virus (HCV)
or human immunodeﬁciency virus co-infection, liver cirrhosis,
and alcohol or drug abuse. Antiviral efﬁcacy was evaluated at
the end of treatment (week 48). Virological response was
deﬁned as an undetectable HBV DNA level as measured with
PCR assay at week 48; non-response was deﬁned as a rebound
of serum HBV DNA levels of 1 log10 IU/mL or greater from
nadir in patients with an initial antiviral treatment effect, as
conﬁrmed by two consecutive determinations over a 1-month
interval [6,7].
Written informed consent was obtained from all patients,
and the study was approved by the Ethical Committee of the
Ruijin Hospital, in accordance with the Helsinki Declaration.
Liver biochemistry, HBV serology, and HBV DNA tests
The liver biochemistry was determined with a routine auto-
mated analysis system (Beckman Coulter, Fullerton, CA, USA)
during every follow-up. HBV serological markers, including
HBsAg, antibody against HBsAg, hepatitis B e antigen (HBeAg)
and antibody against HBeAg were determined every 3 months
with a chemiluminescence microparticle enzyme immunoassay
(Abbott, Chicago, IL, USA). HBV DNA levels were determined
with the Cobas Amplicor HBVMonitor Test (RocheDiagnostics,
Pleasanton, CA, USA), with a lower detection limit of 60 IU/mL.
HBV nucleic acid extraction and target region PCR
ampliﬁcation
HBV DNA was extracted from serum samples collected before
treatment initiation. High-ﬁdelity PCR was applied to amplify
targeted regions. The RT region and overlapping S region of the
HBV genome and the positions of amplicons analysed with NGS
are shown in Fig. 1. RT contig 1 and contig 2 encompassed theFIG. 1. Positions of the three
sequential and overlapping contigs on
the reverse transcriptase (RT) and S
genes. The numbering of the RT nu-
cleotides is shown at the two ends of
the RT gene. The shaded boxes indi-
cate the conserved regions of the RT
domain of the HBV RT region. The
hashed bonds indicate the positions
of the three overlapping contigs used
in this study. The major hydrophilic
region (MHR) of the S gene is
enclosed within dotted lines within
the S gene region. HLA class I and II
restricted epitopes of the S gene are
indicated by wavy bonds and dashed
bonds, respectively.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e1–797.e8
TABLE 1. Demographic and clinical features of the patients
Responders
(n [ 18)
Non-responders
(n [ 18) p
Age (years), median (IQR) 38 (30–42) 33 (25–41) 0.142
Gender (male/female), no. 14/4 14/4 1.000
Baseline HBeAg (+/–), no. 10/8 12/6 0.733
Baseline ALT (IU/L) 105 (77–190) 93 (60–220) 0.915
Baseline viral load (log IU/mL),
median (IQR)
6.312
(5.841–7.468)
6.978 (6.927–7.378) 0.0631
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; IQR, interquartile
range.
CMI Han et al. Virological response predicted by pretreatment HBV RT QS 797.e3ﬁrst two-thirds of the RT gene, and overlapped with most of
the S gene region. The major hydrophilic region of the S gene
and the classic lamivudine-resistant YMDD locus were both
located in contig 2. Detailed methods are given in Doc. S1.
Molecular cloning and sequencing with the Sanger
method
PCR products were puriﬁed and cloned. Positive clones were
identiﬁed by PCR assay and Sanger sequenced. Details are given
in Doc. S1.
NGS sequencing
PCR products were puriﬁed and homogenized for downstream
NGS. Details are given in Doc. S1.
Treatment of sequence data
Raw sequences of clones were aligned to strip gaps with
CLUSTAL X, version 1.83 [8]. Potential recombinant sequences
were detected [9]. Low-quality reads were discarded. Individual
samples were identiﬁed. Noise was further reduced [10]. Reads
were aligned with genomic reference sequences from the
NCBI, and were then collected for downstream analysis. De-
tails are given in Doc. S1.
Pretreatment RT QS sequence analysis
The nature of the viral population was characterized from viral
genetic complexity and diversity, with data from the two
methods. The RT QS complexity was quantiﬁed by Shannon
entropy [11] at both the nucleotide level and the amino acid
level. Diversity was evaluated according to three parameters:
the mean genetic distance (d, also called the Hamming distance),
the number of synonymous substitutions per synonymous site
(dS), and the number of non-synonymous substitutions per
non-synonymous site (dN) [12]. Details are given in Doc. S1.
Statistical analysis
Pretreatment patient characteristics between responders and
non-responders were evaluated for statistical signiﬁcance with
the chi-square test for categorical variables (Fisher’s exact test
was used when needed) and the Mann–Whitney test for
continuous variables, as needed. The results of continuous
variables were expressed as median with interquartile range,
and RT QS heterogeneity values were compared between re-
sponders and non-responders in both methods by the use of
unpaired Student’s t-tests when the dataset passed a normality
check, or the Mann–Whitney test if they did not belong to a
normal distribution. The overall abilities of CBS and NGS to
predict treatment response were compared by the use of
receiver operating characteristic (ROC) curves. Areas under
the curve (AUCs) of the two methods were assessed. ROCClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Incurves were evaluated by reporting a p-value that tests the null
hypothesis that the AUC really equals 0.50. Exhaustive com-
parisons between CBS and each of the three NGS contigs were
also performed [13]. The Kaplan–Meier survival curves were
plotted, and the signiﬁcance of the difference between curves
was calculated by the use of both a log-rank test and the Wil-
coxon test with GraphPad Prism version 6.00 (GraphPad
Software, La Jolla, CA, USA). Statistical analyses were per-
formed with statistical software (SPSS version 20.0; SPSS, Chi-
cago, IL, USA). p-Values of <0.05 were considered to be
statistically signiﬁcant.ResultsDemographic, clinical and laboratory data
Thirty-six patients with chronic hepatitis B were enrolled. The
demographic and clinical features at baseline are shown in
Table 1. Age, gender, HBeAg status, ALT levels and HBV viral
load in responders and non-responders were comparable
(p > 0.05). For CBS methods, on average 20 clones per patient
were chosen for analysis, whereas 3179 reads on average,
ranging from 1016 to 13 656 reads, per contig per patient were
generated by NGS testing.
Pretreatment HBV RT QS genetic heterogeneity of
responders and non-responders
The pretreatment HBV RT QS genetic complexity and diversity
were determined and compared (Fig. 2). Overall, responders
had higher genetic complexity and diversity than non-
responders. The differences were signiﬁcant in a large pro-
portion of the NGS-determined groups. (a) Genetic
complexity: responders had signiﬁcantly higher genetic
complexity than non-responders in RT contigs 1 and 2 by NGS
(Fig. 2), at both the nucleotide level and the amino acid level,
whereas, in CBS testing, the differences were not statistically
signiﬁcant (Fig. 2). When CBS results were further divided into
the same three contigs of NGS testing and compared, there
was still no statistically signiﬁcant difference betweenfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e1–797.e8
FIG. 2. Comparison of baseline hepatitis B virus reverse transcriptase quasispecies genetic characteristics between lamivudine responders and non-
responders calculated on the basis of clone-based Sanger sequencing and next-generation sequencing data.
797.e4 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIresponders and non-responders. (b) Genetic diversity (mean
distance): responders had signiﬁcantly higher genetic mean
distances than non-responders in all three RT regions, ac-
cording to NGS testing (Fig. 2). There was no signiﬁcant dif-
ference in CBS testing. (c) Genetic diversity (dS, synonymous):
there was no statistical signiﬁcance in either the NGS or CBS
groups, except for RT contig 3, according to NGS testing. As
dS did not cause changes in the amino acids coded, as ex-
pected, regardless of the method used, dS values were higher
than dN values in all groups. (d) Genetic diversity (dN, non-
synonymous): in terms of dN, values, which reﬂect selection
strength, responders showed signiﬁcantly higher dN values
than non-responders in all three RT regions, according to NGS
testing (Fig. 2).
Performance of the CBS and NGS approaches: ROC
curves
As the above results suggested that pretreatment RT QS ge-
netic heterogeneity might serve as a predictor of antiviral
therapy outcome, the values of this were then evaluated by the
use of ROC curves (Fig. 3). Generally, NGS groups had higherClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectAUCs than CBS groups. If a test had a p-value of <0.05, it was
considered to have actual discriminatory ability; if it had a p-
value of <0.01, the strength should be stronger. The genetic
complexity and diversity of the ﬁrst two parts of the RT region
(contigs 1 and 2) tested with NGS were able to discriminate
responders from non-responders: (a) Genetic complexity: RT
contig 1 at the nucleotide level and contig 2 at both the
nucleotide level and the amino acid level, according to NGS,
had higher AUCs than the other groups, and could discriminate
responders from non-responders (detailed in Fig. 3). (b) Ge-
netic diversity (mean distance): higher AUCs were found in all
of the NGS groups. Also, NGS testing in all three RT contigs, at
both the nucleotide level and the amino acid level, had statis-
tically signiﬁcant predictive power, whereas CBS did not
(detailed in Fig. 3). (c) Genetic diversity (dS): less signiﬁcance
was found when diversity was determined with this parameter.
RT contig 3, according to NGS testing, was the only group that
had statistically signiﬁcant discriminatory power. Nevertheless,
the NGS groups had higher AUCs than the CBS groups
(detailed in Fig. 3). (d) Genetic diversity (dN): higher AUCs
were also found in all of the NGS groups. Also, NGS testing inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e1–797.e8
FIG. 3. Better prediction of lamivudine responsiveness with next-generation sequencing data (NGS) than with clone-based Sanger sequencing (CBS):
receiver operating characteristic curves of the ability of pretreatment hepatitis B virus reverse transcriptase (RT) quasispecies testing to predict
virological response when it is performed with NGS data (three contigs) or CBS data. The black dashed line represents RT contig 1 by NGS, the black
solid line indicates RT contig 2 by NGS, the black dotted line represents RT contig 3 by CBS, and the grey dashed represents RT by CBS. The legend
shows the area under the curve values (A) for each category. Tests with signiﬁcant discrimination ability between response and non-response groups
are shown in bold type and asterisked (* when p < 0.05, ** when p < 0.01).
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797.e6 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIall three RT contigs had statistically signiﬁcant predictive power,
whereas CBS did not (detailed in Fig. 3). The 95% CI and the
optimal cut-off of each AUC are shown in Table S1. A p-value
summary of the comparisons between CBS and each of the
three NGS contigs is shown in Table S2.
Determination of a cut-off value to discriminate
responders from non-responders
As the mean distance of RT contig 2 had the highest AUC value,
at both the nucleotide level and the amino acid level, the dataset
was further scrutinized for selection of a cut-off value with the
best combination of speciﬁcity and sensitivity. When 0.007186
(the mean distance of RT contig 2 at the amino acid level) was
chosen and set, the plotted Kaplan–Meier survival curves of the
time to virological response (HBV DNA of <60 IU/mL) showed
that the patient group with a distance higher than the cut-off
had a higher probability of achieving virological response over
time, i.e. responded better. Both log-rank and Wilcoxon tests
showed that the two curves were signiﬁcantly different (p
0.0090 in the log-rank test; p 0.0121 in the Wilcoxon test)
(Fig. 4).DiscussionPrevious HBV studies using the CBS method have mentioned
pretreatment HBV QS characteristics in nucleos(t)ide analogueFIG. 4. Kaplan–Meier survival curves of time to virological response
(hepatitis B virus DNA of <60 IU/mL), and genetic mean distance of
reverse transcriptase (RT) contig 2 (amino acid). Next-generation
sequencing (NGS) data were used to calculate the genetic mean dis-
tance at the amino acid level of RT contig 2 among all subjects. A value
of 0.007186 was set as the cut-off. A log-rank (Mantel–Cox) test
showed that the two curves were signiﬁcantly different, with a p-value
of 0.0090**. The Wilcoxon test also generated a p-value of <0.05.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttreatment, but, because no statistical signiﬁcance was found, no
group has ever determined its link to treatment efﬁcacy [14,15].
In contrast to HBV, the HCV QS study with the largest sample
size demonstrated that higher heterogeneity (both complexity
and diversity) was associated with early virological response to
antiviral therapy [16], although previous studies with smaller
samples and less sequencing depth had generated conﬂicting
data with regard to the role of HCV QS in determination of
therapeutic efﬁciency [17,18]. In this study, when NGS was
applied, signiﬁcantly higher baseline QS genetic heterogeneity
within the RT coding region, which overlapped with the S gene,
was found in responders. Baseline NGS testing may predict
treatment outcomes, whereas CBS can hardly predict them
at all.
The fact that higher genetic heterogeneity within the major
hydrophilic region (of surface protein) under strong immune
pressure was associated with virological response needs to be
discussed. Simple organism, such as viruses, are able to evolve
and adjust to the changing environment by mutation alone [19].
This changing environment includes their host’s immune system
[20]. We all know that error-prone replication of HBV,
resulting in a complex QS population within each infected in-
dividual, enables rapid adaptation. QS heterogeneity may reﬂect
the host response [20]. High mutation rates enable viruses to
escape the host immune responses, but low mutation rates
reduce the probability of destroying essential viral genes [21];
between the two detrimental extremities, the mutation rate
should keep pace with the increase in the immune response.
The above theories are in concordance with our ﬁndings that
responders had higher baseline RT QS complexity and that a
signiﬁcant difference was mostly present in the region over-
lapping with the surface antigen-coding gene, which encodes an
HBV protein that is well known for its immune escape ability
[22]. With >90% of the S protein HLA I and HLA II T-cell
epitopes coupled with most of the RT protein HLA I and HLA II
T-cell epitopes [23] (Fig. 1), this region suffers much more
immune pressure than the rest of the RT region. Moreover,
more signiﬁcance was found in the genetic diversity groups than
in the complexity groups. Genetic diversity, which measures
the distance between the least-related viral strains, could be
described as the parameter that reﬂects the ‘broad range of the
arsenal’, whereas complexity measures the degree of hetero-
geneity. Thus, diversity better reﬂects the capacity of a QS to
promptly adapt to environmental changes.
Depletion of an efﬁcient immune response is the leading
cause of chronicity in HBV infection. As we know that the
persistence of HBV infection is more likely to occur following
vertical transmission (from mother to child) or horizontal
transmission to children or to immunocompromised adults
[24], it can be largely attributed to immune impotency,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e1–797.e8
CMI Han et al. Virological response predicted by pretreatment HBV RT QS 797.e7including the innate [25] and adaptive immune responses [26].
A large body of evidence has indicated that the outcome of
HBV infection and the pathogenesis of the attendant liver dis-
eases are determined by immune-mediated host–virus in-
teractions [27]. However, few studies have focused on the
relationship between HBV QS variety and host immune status.
Even so, among these few studies, there is evidence linking viral
QS to host immunity [28]; a follow-up study of patients
receiving immune system inhibitors would be an appropriate
way to unveil the relevance of host and viral QS status. Among
the very few studies on this subject, researchers have assessed
the mutation patterns and QS heterogeneity in 16 occult
hepatitis B patients undergoing chemotherapy, three of whom
experienced occult hepatitis B reactivation [29]. Under immune
suppression and upon viral reactivation, the QS evolved to-
wards a loss of most of the variants present during the initial
stage.
The above evidence and our ﬁndings imply that a lower
immune response leads to lower RT QS variety. This leads to
the hypothesis that, if higher RT QS heterogeneity indicates a
relatively efﬁcient host immune response, these patients should
have more chance of gaining beneﬁt from antiviral therapy.
International guidelines all recommend that patient be treated
in the immune active phase (as judged by ALT level) rather than
the tolerant phase [30]. Knowledge of the potential driving
force of viral population heterogeneity would make it easier to
understand the predictive value of baseline RT QS heteroge-
neity in antiviral treatment.ConclusionsThis is the ﬁrst time that higher baseline HBV RT QS hetero-
geneity has been proven to be associated with antiviral treat-
ment response. The interaction between viral QS and the host
immune system may contribute to treatment outcome. NGS,
but not CBS, has clinical value in predicting treatment efﬁcacy.Transparency declarationThe authors state that they have no conﬂicts of interest.AcknowledgementsThis work was supported by grants from the Science and
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